Drug Combinations
"Drug Combinations" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
| Descriptor ID |
D004338
|
| MeSH Number(s) |
D26.310
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Combinations".
Below are MeSH descriptors whose meaning is more specific than "Drug Combinations".
- Drug Combinations
- Adapalene, Benzoyl Peroxide Drug Combination
- Albuterol, Ipratropium Drug Combination
- Aminophylline
- Amlodipine Besylate, Olmesartan Medoxomil Drug Combination
- Amlodipine, Valsartan Drug Combination
- Aspirin, Dipyridamole Drug Combination
- Biphasic Insulins
- Brimonidine Tartrate, Timolol Maleate Drug Combination
- Budesonide, Formoterol Fumarate Drug Combination
- Buprenorphine, Naloxone Drug Combination
- Contraceptives, Oral, Combined
- Dimenhydrinate
- Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Emtricitabine, Rilpivirine, Tenofovir Drug Combination
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Ezetimibe, Simvastatin Drug Combination
- Fluticasone-Salmeterol Drug Combination
- Mometasone Furoate, Formoterol Fumarate Drug Combination
- Multi-Ingredient Cold, Flu, and Allergy Medications
- Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
- Trimethoprim, Sulfamethoxazole Drug Combination
This graph shows the total number of publications written about "Drug Combinations" by people in this website by year, and whether "Drug Combinations" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 | | 1997 | 0 | 3 | 3 | | 1999 | 0 | 4 | 4 | | 2000 | 0 | 2 | 2 | | 2001 | 0 | 4 | 4 | | 2002 | 0 | 3 | 3 | | 2003 | 0 | 6 | 6 | | 2004 | 0 | 6 | 6 | | 2005 | 0 | 5 | 5 | | 2006 | 0 | 6 | 6 | | 2007 | 0 | 4 | 4 | | 2008 | 0 | 6 | 6 | | 2009 | 0 | 7 | 7 | | 2010 | 0 | 9 | 9 | | 2011 | 2 | 10 | 12 | | 2012 | 0 | 7 | 7 | | 2013 | 0 | 8 | 8 | | 2014 | 1 | 8 | 9 | | 2015 | 0 | 5 | 5 | | 2016 | 0 | 13 | 13 | | 2017 | 0 | 12 | 12 | | 2018 | 0 | 16 | 16 | | 2019 | 0 | 14 | 14 | | 2020 | 0 | 11 | 11 | | 2021 | 0 | 22 | 22 | | 2022 | 0 | 14 | 14 | | 2023 | 0 | 10 | 10 | | 2024 | 3 | 10 | 13 | | 2025 | 0 | 20 | 20 | | 2026 | 0 | 21 | 21 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Combinations" by people in Profiles.
-
Han WM, Solomon S, Wagner-Cardoso S, Li J, Parvangada A, Sulkowski M, Naggie S, Martin R, Mo H, Maiorova E, Wyles D. Rare and Novel Hepatitis C Virus Genotype Subtypes and Response to Sofosbuvir/Velpatasvir in A5360 (MINMON) Clinical Trial. J Viral Hepat. 2026 Nov; 33(11).
-
Chmiel JF, McBennett K, Quon BS, Colombo C, De Wachter E, Fajac I, Mondejar-Lopez P, Polineni D, Robinson P, Sutharsan S, Mall MA, McKone EF, Ramsey B, Taylor-Cousar JL, Tullis E, Suresh NE, Zhang Y, Sosnay P, Jennings M, Barry PJ. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: results from an open-label extension study. Ann Am Thorac Soc. 2026 Sep 01; 23(9):1286-1295.
-
Cherne MD, Gattiker JL, Lyon KN, Russell D, Sebrell TA, Burcham-Carter A, Richard AP, Mathew EN, Mackintosh SG, Gorzalski AJ, Bimczok D. Human gastric extracellular matrix hydrogels maintain organoid growth and reduce gene expression associated with stemness and inflammation. Biomed Mater. 2026 08 17; 21(4).
-
Duncan CL, von Isenburg M, Green A, Ford C, Pucci A, Muther EF, Riekert KA, Bord E, Hoppe JE, Bacon C, Goodman A, Lyons E, Prickett M, Gibson SL, Everhart RS. Caregiver Mental Health and Its Relation to Child and Adolescent Mental and Behavioral Health in the Era of Highly Effective Modulator Therapy for Cystic Fibrosis. Pediatr Pulmonol. 2026 Aug; 61(8):e71794.
-
Baltas I, Drury K, Harrison T, Moore N, Lester R, Chattaway MA, England B, Cattrall JWS, Donaldson CJ, Jamal Khan DP, Carroll A, Ball D, Wareham DW, Pahalage R, Banavathi K, Drazho B, Shorrocks RE, Hlaing W, Adhikaree N, Ryan F, Thompson JV, Connolly G, Shibu P, Ale E, Mirfenderesky M, Jain S, Fowler S, Beard K, Hughes G, Bonnici G, Mohammed T, Brown K, Drazich-Taylor S, Martinez AS, Lipworth S, Crawford-Jones D, Elnour M, Moore J, Democratis J, McCormick J, Hussain A, Islam J, Jenkins D, Stoesser N, Hopkins K, Demirjian A, Hatcher J, Soares AL, Kirby A, Grandjean L. Carbapenem-resistant Enterobacterales across the UK: A nationwide study of carbapenemase testing and novel antimicrobial activity. Int J Antimicrob Agents. 2026 Oct; 67(10):107898.
-
Chalamalla AR, Baker E, Ryan KJ, Dowell A, Natt JR, Zemanick ET, Konstan MW, Mayer-Hamblett N, Acosta EP, Guimbellot JS. Impact of CFTR modulator concentrations on clinical response in cystic fibrosis. Eur Respir J. 2026 Jun; 67(6).
-
Muther EF, Gibson SL, Ford C, Duncan C, Riekert KA, Lyons E, Hoppe JE, Prickett M, Isenburg MV, Everhart RS. People with cystic fibrosis' experience of symptom burden while taking elexacaftor/tezacaftor/ivacaftor. Respir Med. 2026 Aug; 259:108908.
-
Kunz Coyne AJ, Judd C, Lucas K, Al Musawa M, Van Helden S, Holger D, Althubyani A, Yost C, VanDorf S, Mynatt R, Kufel WD, Hayes J, Deri CR, Wrenn RH, Slaton CN, Morrisette T, Davis M, Cabanilla MG, Shald E, White BP, Sassine J, Truong J, Rosenberg J, Andrade J, Cerenzio J, Medvedeva N, Ha D, Eubank TA, Garey KW, Biagi M, Todd M, Kang-Birken SL, Rux C, Molina KC, Jankowski CA, Claeys KC, Venugopalan V, Veve MP, Orzol C, Eshaya M, Caniff KE, Bleick C, Rybak MJ. Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers. Antimicrob Agents Chemother. 2026 06 03; 70(6):e0026826.
-
Kamao T, Yamada M, Shiraishi A, Sakai J, Ohashi Y. Incidence and risk factors related to ocular adverse effects caused by S-1 chemotherapy. Jpn J Ophthalmol. 2026 May; 70(3):527-537.
-
Downey DG, Houston C, Mayer-Hamblett N, Taylor-Cousar JL, Taggart CC. Contributors to the heterogeneity of response to CFTR modulators. Lancet Respir Med. 2026 Aug; 14(8):717-729.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|